Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNP7787 + cisplatin + paclitaxel
- Development stage
- Unknown
- Lead developer
- BioNumerik Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
BNP7787 + cisplatin + paclitaxel is a combination therapy consisting of a chemoprotective agent (BNP7787) with two chemotherapeutic drugs (cisplatin and paclitaxel). BNP7787 (also known as Tavocept or dimesna) is designed to prevent and mitigate toxicities associated with platinum-based chemotherapeutics and taxanes, particularly neurotoxicity and nephrotoxicity. The combination is primarily studied for the treatment of advanced non-small cell lung cancer (NSCLC).
- Other names
- disodium 2,2'-dithio-bis ethane sulfonate
02
Targets
TXN (Thioredoxin-1)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on BNP7787 + cisplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNP7787 + cisplatin + paclitaxel.